Artiva Biotherapeutics prices USD 300 million follow-on equity offering at USD 11.52/share

Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV

0.00
  • Artiva Biotherapeutics priced an underwritten follow-on offering expected to raise about USD 300 million in gross proceeds.
  • Deal consists of 23,871,526 common shares priced at USD 11.52 per share.
  • Offering also includes pre-funded warrants for 2,170,138 common shares priced at USD 11.52, with a USD 0.0001 per-share exercise price.
  • Closing expected around May 11, 2026, subject to customary conditions.
  • Jefferies, TD Cowen, Cantor acting as joint book-running managers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080652PRIMZONEFULLFEED9716391) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.